Wealthfront Advisers LLC Vertex Pharmaceuticals Inc Transaction History
Wealthfront Advisers LLC
- $32.2 Billion
- Q3 2024
A detailed history of Wealthfront Advisers LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Wealthfront Advisers LLC holds 39,200 shares of VRTX stock, worth $15.9 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
39,200
Previous 39,690
1.23%
Holding current value
$15.9 Million
Previous $18.6 Million
2.0%
% of portfolio
0.06%
Previous 0.06%
Shares
24 transactions
Others Institutions Holding VRTX
# of Institutions
1,724Shares Held
221MCall Options Held
1.58MPut Options Held
1.36M-
Capital World Investors Los Angeles, CA26.8MShares$10.9 Billion1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.2MShares$9.39 Billion0.2% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$8.64 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.8MShares$4.79 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA9MShares$3.65 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $104B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...